TransMedics Group Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

TMDX$93.79+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TransMedics Group, Inc.
Date: February 27, 2025	By:	/s/ Gerardo Hernandez
		Gerardo Hernandez
		Chief Financial Officer and Treasurer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Waleed H. Hassanein
Name	Title	Date
/s/ Waleed H. Hassanein, M.D.	President, Chief Executive Officer, Director	February 27, 2025
/s/ Gerardo Hernandez	Chief Financial Officer and Treasurer	February 27, 2025
Gerardo Hernandez
/s/ James R. Tobin	Chairman of the Board of Directors	February 27, 2025
James R. Tobin
/s/ Edward M. Basile	Director	February 27, 2025
Edward M. Basile
/s/ Thomas J. Gunderson	Director	February 27, 2025
Thomas J. Gunderson
/s/ Edwin M. Kania, Jr.	Director	February 27, 2025
Edwin M. Kania, Jr.
/s/ David Weill, M.D.	Director	February 27, 2025
David Weill, M.D.
/s/ Merilee Raines	Director	February 27, 2025
Merilee Raines
/s/ Stephanie Lovell	Director	February 27, 2025
Stephanie Lovell

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.